Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:0
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [11] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    BMC Cancer, 9 (1)
  • [12] Current approaches for identifying high-risk non-muscle invasive bladder cancer
    Sanli, Oner
    Lotan, Yair
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 223 - 235
  • [13] Association of BCG shortage with bladder cancer recurrence in high-risk non-muscle invasive bladder cancer
    Lee, Sangmin
    Lim, Bumjin
    You, Dalsan
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Kim, Choung-Soo
    Jeong, In Gab
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 26 - 27
  • [14] Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France
    Saint, Fabien
    Pasquier, David
    Villers, Arnauld
    Massa, Jordan
    Colin, Pierre
    Vankemmel, Olivier
    Leroy, Xavier
    Bonnal, Jean-Louis
    Plouvier, Sandrine D.
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (09):
  • [15] No 'one size fits all' approach in the management of high-risk non-muscle invasive bladder cancer
    Mostafid, Hugh
    SCANDINAVIAN JOURNAL OF UROLOGY, 2021, 55 (01) : 53 - 53
  • [16] Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer
    Ahdoot, Michael
    Theodorescu, Dan
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) : 1345 - 1352
  • [17] Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer
    Diamant, Elliott
    Roumiguie, Mathieu
    Ingels, Alexandre
    Parra, Jerome
    Vordos, Dimitri
    Bajeot, Anne-Sophie
    Chartier-Kastler, Emmanuel
    Soulie, Michel
    de la Taille, Alexandre
    Roupret, Morgan
    Seisen, Thomas
    CANCERS, 2022, 14 (15)
  • [18] Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer
    Kramer, M. W.
    Gakis, G.
    UROLOGE, 2020, 59 (07): : 784 - 789
  • [19] URINARY EXTRACELLULAR VESICLE RNA BIOMARKERS FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Minami, Keita
    Osawa, Takahiro
    Murakami, Taku
    Harada, Hiroshi
    Harabayashi, Toru
    Takada, Norikata
    Kashiwagi, Akira
    Hirakawa, Kazushi
    Sato, Yasuyuki
    Matsumoto, Ryuji
    Kikuchi, Hiroshi
    Abe, Takashige
    Murai, Sachiyo
    Shinohara, Nobuo
    JOURNAL OF UROLOGY, 2020, 203 : E1008 - E1009
  • [20] Chromosomal Imbalance in the Progression of High-Risk Non-Muscle Invasive Bladder Cancer Editorial Comment
    Montie, James E.
    JOURNAL OF UROLOGY, 2010, 183 (03): : 938 - 939